Name | Number of supported studies | Average coverage | |
---|---|---|---|
cardiac muscle cell | 6 studies | 50% ± 13% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
heart | 5 studies | 21% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ureter | 0% | 0 | 0 / 0 | 100% | 1.23 | 1 / 1 |
heart | 100% | 44933.33 | 860 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 22659.08 | 796 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 20% | 11.16 | 9 / 45 |
prostate | 7% | 241.09 | 18 / 245 | 11% | 8.51 | 56 / 502 |
uterus | 1% | 2.24 | 1 / 170 | 7% | 5.64 | 34 / 459 |
skin | 0% | 4.72 | 8 / 1809 | 5% | 0.78 | 24 / 472 |
blood vessel | 3% | 179.12 | 35 / 1335 | 0% | 0 | 0 / 0 |
breast | 2% | 30.68 | 8 / 459 | 1% | 0.52 | 9 / 1118 |
thymus | 2% | 17.49 | 10 / 653 | 1% | 0.39 | 4 / 605 |
lung | 1% | 56.24 | 6 / 578 | 1% | 0.15 | 12 / 1155 |
brain | 0% | 1.21 | 6 / 2642 | 2% | 0.02 | 11 / 705 |
peripheral blood | 2% | 15.05 | 16 / 929 | 0% | 0 | 0 / 0 |
ovary | 0% | 0 | 0 / 180 | 2% | 0.04 | 7 / 430 |
stomach | 0% | 0 | 0 / 359 | 1% | 0.03 | 4 / 286 |
bladder | 0% | 0 | 0 / 21 | 1% | 0.08 | 5 / 504 |
esophagus | 1% | 25.99 | 14 / 1445 | 0% | 0 | 0 / 183 |
adipose | 1% | 7.99 | 11 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 0% | 1.95 | 1 / 328 | 1% | 0.01 | 1 / 178 |
adrenal gland | 0% | 4.45 | 1 / 258 | 0% | 0.08 | 1 / 230 |
intestine | 0% | 1.81 | 2 / 966 | 0% | 0.00 | 2 / 527 |
kidney | 0% | 0 | 0 / 89 | 1% | 0.03 | 5 / 901 |
liver | 0% | 0 | 0 / 226 | 0% | 0.02 | 2 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
GO_0007519 | Biological process | skeletal muscle tissue development |
GO_0006954 | Biological process | inflammatory response |
GO_0046716 | Biological process | muscle cell cellular homeostasis |
GO_0002026 | Biological process | regulation of the force of heart contraction |
GO_0003300 | Biological process | cardiac muscle hypertrophy |
GO_0006874 | Biological process | intracellular calcium ion homeostasis |
GO_0033365 | Biological process | protein localization to organelle |
GO_0060048 | Biological process | cardiac muscle contraction |
GO_0055003 | Biological process | cardiac myofibril assembly |
GO_0060537 | Biological process | muscle tissue development |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0033292 | Biological process | T-tubule organization |
GO_0035995 | Biological process | detection of muscle stretch |
GO_0048738 | Biological process | cardiac muscle tissue development |
GO_0045214 | Biological process | sarcomere organization |
GO_0070528 | Biological process | protein kinase C signaling |
GO_1903076 | Biological process | regulation of protein localization to plasma membrane |
GO_0042593 | Biological process | glucose homeostasis |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005856 | Cellular component | cytoskeleton |
GO_0030018 | Cellular component | Z disc |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008307 | Molecular function | structural constituent of muscle |
GO_0042802 | Molecular function | identical protein binding |
GO_0031433 | Molecular function | telethonin binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0042805 | Molecular function | actinin binding |
GO_0005515 | Molecular function | protein binding |
GO_0003779 | Molecular function | actin binding |
Gene name | CSRP3 |
Protein name | Cysteine and glycine-rich protein 3 (Cardiac LIM protein) (Cysteine-rich protein 3) (CRP3) (LIM domain protein, cardiac) (Muscle LIM protein) Cysteine and glycine-rich protein 3 (Cardiac LIM protein) (cDNA, FLJ93801, Homo sapiens cysteine and glycine-rich protein 3 (cardiac LIMprotein) (CSRP3), mRNA) Cysteine and glycine rich protein 3 |
Synonyms | MLP hCG_1811041 CLP |
Description | FUNCTION: Positive regulator of myogenesis. Acts as a cofactor for myogenic bHLH transcription factors such as MYOD1, and probably MYOG and MYF6. Enhances the DNA-binding activity of the MYOD1:TCF3 isoform E47 complex and may promote formation of a functional MYOD1:TCF3 isoform E47:MEF2A complex involved in myogenesis (By similarity). Plays a crucial and specific role in the organization of cytosolic structures in cardiomyocytes. Could play a role in mechanical stretch sensing. May be a scaffold protein that promotes the assembly of interacting proteins at Z-line structures. It is essential for calcineurin anchorage to the Z line. Required for stress-induced calcineurin-NFAT activation (By similarity). The role in regulation of cytoskeleton dynamics by association with CFL2 is reported conflictingly: Shown to enhance CFL2-mediated F-actin depolymerization dependent on the CSRP3:CFL2 molecular ratio, and also shown to reduce the ability of CLF1 and CFL2 to enhance actin depolymerization . Proposed to contribute to the maintenance of muscle cell integrity through an actin-based mechanism. Can directly bind to actin filaments, cross-link actin filaments into bundles without polarity selectivity and protect them from dilution- and cofilin-mediated depolymerization; the function seems to involve its self-association . In vitro can inhibit PKC/PRKCA activity . Proposed to be involved in cardiac stress signaling by down-regulating excessive PKC/PRKCA signaling (By similarity). .; FUNCTION: [Isoform 2]: May play a role in early sarcomere organization. Overexpression in myotubes negatively regulates myotube differentiation. By association with isoform 1 and thus changing the CSRP3 isoform 1:CFL2 stoichiometry is proposed to down-regulate CFL2-mediated F-actin depolymerization. . |
Accessions | A0A3B3IRI5 ENST00000533783.2 [P50461-1] ENST00000647990.1 P50461 A0A3B3ISZ2 A0A7R6RQ65 A0A7R6RR27 A0A3B3IT61 ENST00000649842.1 ENST00000649235.1 [P50461-1] A2TDB8 ENST00000265968.9 [P50461-1] ENST00000648719.1 |